| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroendocrine Tumors | 27 | 2024 | 105 | 11.930 |
Why?
|
| Pancreatic Neoplasms | 26 | 2024 | 645 | 7.840 |
Why?
|
| Intestinal Neoplasms | 6 | 2024 | 56 | 3.220 |
Why?
|
| Adrenocortical Carcinoma | 4 | 2020 | 12 | 2.870 |
Why?
|
| Adrenal Cortex Neoplasms | 4 | 2020 | 18 | 2.860 |
Why?
|
| Stomach Neoplasms | 6 | 2024 | 266 | 2.700 |
Why?
|
| Positron Emission Tomography Computed Tomography | 7 | 2022 | 86 | 1.870 |
Why?
|
| Thyroid Neoplasms | 12 | 2023 | 408 | 1.840 |
Why?
|
| Organometallic Compounds | 7 | 2020 | 132 | 1.820 |
Why?
|
| Pancreatectomy | 5 | 2020 | 148 | 1.630 |
Why?
|
| Liver Neoplasms | 5 | 2023 | 736 | 1.360 |
Why?
|
| Thyroid Nodule | 5 | 2023 | 51 | 1.300 |
Why?
|
| Pancreas | 4 | 2019 | 239 | 1.240 |
Why?
|
| Thyroidectomy | 6 | 2022 | 170 | 1.110 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2020 | 81 | 1.060 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2022 | 28 | 1.010 |
Why?
|
| Radiopharmaceuticals | 4 | 2020 | 180 | 0.970 |
Why?
|
| Hyperparathyroidism, Primary | 2 | 2016 | 41 | 0.960 |
Why?
|
| von Hippel-Lindau Disease | 3 | 2021 | 17 | 0.930 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 2 | 2020 | 10 | 0.870 |
Why?
|
| Neoplasm Staging | 6 | 2020 | 1939 | 0.840 |
Why?
|
| Retrospective Studies | 20 | 2023 | 8489 | 0.840 |
Why?
|
| Catheter Ablation | 1 | 2023 | 233 | 0.790 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2020 | 159 | 0.770 |
Why?
|
| Humans | 61 | 2024 | 86643 | 0.770 |
Why?
|
| Middle Aged | 31 | 2023 | 25028 | 0.770 |
Why?
|
| Octreotide | 1 | 2020 | 16 | 0.750 |
Why?
|
| Coordination Complexes | 1 | 2020 | 19 | 0.750 |
Why?
|
| Margins of Excision | 1 | 2020 | 39 | 0.730 |
Why?
|
| Adrenalectomy | 1 | 2019 | 43 | 0.720 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2020 | 54 | 0.720 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 257 | 0.710 |
Why?
|
| Hepatectomy | 6 | 2023 | 166 | 0.710 |
Why?
|
| Insulinoma | 2 | 2016 | 37 | 0.700 |
Why?
|
| Biomarkers, Tumor | 6 | 2020 | 1464 | 0.690 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2022 | 645 | 0.680 |
Why?
|
| Gallium Radioisotopes | 1 | 2018 | 32 | 0.680 |
Why?
|
| Male | 35 | 2023 | 40965 | 0.680 |
Why?
|
| Abdominal Neoplasms | 1 | 2019 | 39 | 0.680 |
Why?
|
| Female | 38 | 2023 | 44532 | 0.660 |
Why?
|
| Aged | 24 | 2021 | 18415 | 0.640 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 468 | 0.640 |
Why?
|
| MicroRNAs | 4 | 2023 | 534 | 0.630 |
Why?
|
| Parathyroid Hormone | 2 | 2016 | 218 | 0.620 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 120 | 0.600 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2013 | 93 | 0.600 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2016 | 1 | 0.580 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 153 | 0.560 |
Why?
|
| Carcinoma, Islet Cell | 1 | 2015 | 3 | 0.560 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 222 | 0.550 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 243 | 0.550 |
Why?
|
| Thyroid Gland | 3 | 2016 | 270 | 0.520 |
Why?
|
| Catheterization | 2 | 2014 | 232 | 0.510 |
Why?
|
| Viscera | 1 | 2014 | 17 | 0.490 |
Why?
|
| Reperfusion | 1 | 2014 | 31 | 0.480 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 582 | 0.480 |
Why?
|
| Reoperation | 1 | 2016 | 597 | 0.470 |
Why?
|
| Postoperative Complications | 4 | 2023 | 2207 | 0.470 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2014 | 78 | 0.460 |
Why?
|
| Surgeons | 3 | 2023 | 238 | 0.460 |
Why?
|
| Pathology, Molecular | 1 | 2013 | 34 | 0.460 |
Why?
|
| Adult | 25 | 2021 | 25648 | 0.450 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 1135 | 0.440 |
Why?
|
| Calcimimetic Agents | 1 | 2012 | 5 | 0.430 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 4 | 2021 | 15 | 0.420 |
Why?
|
| Survival Rate | 4 | 2020 | 1863 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2020 | 1197 | 0.400 |
Why?
|
| Carcinoma | 4 | 2023 | 436 | 0.380 |
Why?
|
| Aspergillosis | 2 | 2008 | 41 | 0.380 |
Why?
|
| Carcinoma, Papillary | 6 | 2016 | 158 | 0.380 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2010 | 30 | 0.380 |
Why?
|
| United States | 7 | 2023 | 6672 | 0.380 |
Why?
|
| Organ Transplantation | 1 | 2014 | 265 | 0.370 |
Why?
|
| Databases, Factual | 5 | 2021 | 814 | 0.370 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2010 | 42 | 0.360 |
Why?
|
| Tissue and Organ Procurement | 1 | 2014 | 311 | 0.360 |
Why?
|
| Survival Analysis | 3 | 2021 | 1538 | 0.360 |
Why?
|
| Mutation | 6 | 2023 | 3968 | 0.350 |
Why?
|
| Treatment Outcome | 10 | 2023 | 7993 | 0.350 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 3640 | 0.340 |
Why?
|
| Colectomy | 1 | 2010 | 167 | 0.340 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 2360 | 0.320 |
Why?
|
| Prognosis | 8 | 2021 | 3679 | 0.320 |
Why?
|
| Latex Fixation Tests | 1 | 2007 | 1 | 0.310 |
Why?
|
| Multivariate Analysis | 4 | 2019 | 999 | 0.300 |
Why?
|
| Hematologic Neoplasms | 2 | 2008 | 329 | 0.300 |
Why?
|
| Disease-Free Survival | 3 | 2019 | 1204 | 0.290 |
Why?
|
| Adolescent | 10 | 2021 | 8981 | 0.290 |
Why?
|
| Postoperative Period | 2 | 2019 | 303 | 0.290 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 376 | 0.280 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 559 | 0.270 |
Why?
|
| SEER Program | 2 | 2015 | 190 | 0.260 |
Why?
|
| Prospective Studies | 7 | 2022 | 4213 | 0.250 |
Why?
|
| Hemangioblastoma | 2 | 2021 | 12 | 0.250 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 1208 | 0.240 |
Why?
|
| Pheochromocytoma | 2 | 2021 | 49 | 0.240 |
Why?
|
| Parathyroidectomy | 2 | 2016 | 78 | 0.240 |
Why?
|
| Young Adult | 10 | 2021 | 5976 | 0.240 |
Why?
|
| Microwaves | 1 | 2023 | 34 | 0.230 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 526 | 0.230 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2021 | 80 | 0.230 |
Why?
|
| Propensity Score | 2 | 2021 | 136 | 0.230 |
Why?
|
| Morbidity | 1 | 2024 | 148 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2020 | 3362 | 0.230 |
Why?
|
| Bone Density | 2 | 2016 | 209 | 0.230 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2020 | 138 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2021 | 860 | 0.220 |
Why?
|
| Positron-Emission Tomography | 3 | 2020 | 329 | 0.220 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2023 | 73 | 0.220 |
Why?
|
| Recurrent Laryngeal Nerve Injuries | 1 | 2022 | 17 | 0.220 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 1036 | 0.210 |
Why?
|
| Hashimoto Disease | 2 | 2020 | 10 | 0.210 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2022 | 46 | 0.210 |
Why?
|
| Risk Factors | 5 | 2020 | 5417 | 0.210 |
Why?
|
| Genotype | 2 | 2017 | 1851 | 0.210 |
Why?
|
| Operative Time | 2 | 2019 | 127 | 0.210 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2022 | 72 | 0.200 |
Why?
|
| Chromogranin A | 1 | 2021 | 8 | 0.200 |
Why?
|
| Predictive Value of Tests | 5 | 2021 | 1673 | 0.200 |
Why?
|
| Jejunal Neoplasms | 1 | 2021 | 9 | 0.200 |
Why?
|
| Chondroitin Sulfates | 1 | 2021 | 43 | 0.200 |
Why?
|
| Ileal Neoplasms | 1 | 2021 | 9 | 0.200 |
Why?
|
| Tumor Burden | 2 | 2019 | 289 | 0.200 |
Why?
|
| Multimodal Imaging | 3 | 2017 | 110 | 0.200 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2020 | 13 | 0.190 |
Why?
|
| Hydrogels | 1 | 2021 | 82 | 0.190 |
Why?
|
| Adrenal Cortex | 1 | 2020 | 21 | 0.190 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 56 | 0.190 |
Why?
|
| Mitotane | 1 | 2019 | 2 | 0.180 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 859 | 0.180 |
Why?
|
| Lymphatic Metastasis | 2 | 2020 | 486 | 0.180 |
Why?
|
| ras Proteins | 1 | 2020 | 128 | 0.180 |
Why?
|
| DNA Repair | 1 | 2022 | 356 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 2438 | 0.180 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 178 | 0.180 |
Why?
|
| Liver | 2 | 2017 | 1230 | 0.180 |
Why?
|
| Hormone Replacement Therapy | 1 | 2020 | 77 | 0.180 |
Why?
|
| Calcium | 2 | 2016 | 1156 | 0.180 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 429 | 0.170 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 123 | 0.170 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 38 | 0.170 |
Why?
|
| Digestive System Neoplasms | 1 | 2018 | 20 | 0.170 |
Why?
|
| Adrenal Glands | 1 | 2018 | 76 | 0.170 |
Why?
|
| Thymus Neoplasms | 1 | 2018 | 41 | 0.160 |
Why?
|
| Whole Genome Sequencing | 1 | 2019 | 76 | 0.160 |
Why?
|
| Child | 3 | 2021 | 6927 | 0.160 |
Why?
|
| Serum Albumin | 1 | 2019 | 130 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2016 | 2601 | 0.160 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 916 | 0.160 |
Why?
|
| Transcriptome | 2 | 2020 | 580 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2017 | 13 | 0.160 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2017 | 28 | 0.160 |
Why?
|
| Gene Ontology | 1 | 2017 | 34 | 0.160 |
Why?
|
| Blood Coagulation Disorders | 1 | 2019 | 63 | 0.160 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 6509 | 0.160 |
Why?
|
| Hypertrophy | 1 | 2017 | 62 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 454 | 0.150 |
Why?
|
| Liver Regeneration | 1 | 2017 | 32 | 0.150 |
Why?
|
| Perioperative Care | 1 | 2019 | 161 | 0.150 |
Why?
|
| Registries | 1 | 2021 | 702 | 0.150 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 1056 | 0.150 |
Why?
|
| Sensitivity and Specificity | 3 | 2012 | 1991 | 0.150 |
Why?
|
| Portal Vein | 1 | 2017 | 120 | 0.150 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 302 | 0.150 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 106 | 0.150 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 1753 | 0.150 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 318 | 0.150 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 133 | 0.150 |
Why?
|
| RNA-Binding Proteins | 1 | 2019 | 246 | 0.140 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2016 | 15 | 0.140 |
Why?
|
| Cluster Analysis | 1 | 2017 | 369 | 0.140 |
Why?
|
| Intraoperative Period | 1 | 2016 | 90 | 0.140 |
Why?
|
| Parathyroid Glands | 1 | 2016 | 74 | 0.140 |
Why?
|
| Goiter | 1 | 2016 | 43 | 0.140 |
Why?
|
| Pancreatic Cyst | 1 | 2016 | 28 | 0.140 |
Why?
|
| Radionuclide Imaging | 1 | 2016 | 220 | 0.140 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 621 | 0.140 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1686 | 0.140 |
Why?
|
| Gene Expression Profiling | 3 | 2020 | 1384 | 0.140 |
Why?
|
| Repressor Proteins | 1 | 2019 | 403 | 0.130 |
Why?
|
| Anticoagulants | 1 | 2019 | 408 | 0.130 |
Why?
|
| Patient Selection | 1 | 2019 | 685 | 0.130 |
Why?
|
| Support Vector Machine | 2 | 2012 | 25 | 0.130 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 2426 | 0.130 |
Why?
|
| Transplantation, Autologous | 1 | 2016 | 331 | 0.130 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2015 | 56 | 0.130 |
Why?
|
| Cohort Studies | 5 | 2022 | 2767 | 0.130 |
Why?
|
| Ribonuclease III | 1 | 2014 | 14 | 0.130 |
Why?
|
| Lymph Node Excision | 2 | 2021 | 217 | 0.130 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 384 | 0.130 |
Why?
|
| Precancerous Conditions | 1 | 2016 | 196 | 0.120 |
Why?
|
| Incidence | 1 | 2019 | 1577 | 0.120 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2014 | 62 | 0.120 |
Why?
|
| Hypothyroidism | 1 | 2016 | 232 | 0.120 |
Why?
|
| DNA Methylation | 1 | 2019 | 628 | 0.120 |
Why?
|
| Ultrasonography | 1 | 2016 | 695 | 0.120 |
Why?
|
| Recurrence | 1 | 2016 | 1139 | 0.110 |
Why?
|
| Diagnosis, Differential | 3 | 2012 | 1565 | 0.110 |
Why?
|
| Splenomegaly | 1 | 2013 | 27 | 0.110 |
Why?
|
| Splenectomy | 1 | 2013 | 82 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 879 | 0.110 |
Why?
|
| Time Factors | 2 | 2018 | 5210 | 0.110 |
Why?
|
| Animals | 3 | 2021 | 26582 | 0.110 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2013 | 64 | 0.110 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 394 | 0.110 |
Why?
|
| Hemostasis, Surgical | 1 | 2012 | 26 | 0.100 |
Why?
|
| Abdominal Injuries | 1 | 2012 | 39 | 0.100 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2011 | 71 | 0.100 |
Why?
|
| Intestinal Obstruction | 1 | 2012 | 88 | 0.100 |
Why?
|
| Duodenal Neoplasms | 1 | 2011 | 19 | 0.100 |
Why?
|
| Hernia, Inguinal | 1 | 2012 | 67 | 0.100 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 938 | 0.100 |
Why?
|
| Choristoma | 1 | 2011 | 68 | 0.100 |
Why?
|
| Laparoscopy | 2 | 2019 | 754 | 0.090 |
Why?
|
| Intestine, Small | 1 | 2012 | 303 | 0.090 |
Why?
|
| Adenoma | 1 | 2012 | 235 | 0.090 |
Why?
|
| Phenotype | 1 | 2016 | 2378 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 427 | 0.090 |
Why?
|
| Embolization, Therapeutic | 1 | 2012 | 238 | 0.090 |
Why?
|
| Aspergillus flavus | 1 | 2008 | 1 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2011 | 712 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 579 | 0.080 |
Why?
|
| Fractures, Ununited | 1 | 2008 | 7 | 0.080 |
Why?
|
| Equipment and Supplies | 1 | 2008 | 30 | 0.080 |
Why?
|
| Scaphoid Bone | 1 | 2008 | 7 | 0.080 |
Why?
|
| Biofilms | 1 | 2008 | 42 | 0.080 |
Why?
|
| Chelating Agents | 1 | 2008 | 69 | 0.080 |
Why?
|
| Logistic Models | 1 | 2012 | 1186 | 0.080 |
Why?
|
| Disease Progression | 3 | 2018 | 1531 | 0.080 |
Why?
|
| Bone Screws | 1 | 2008 | 44 | 0.080 |
Why?
|
| Bone Transplantation | 1 | 2008 | 64 | 0.080 |
Why?
|
| Neutropenia | 1 | 2008 | 215 | 0.080 |
Why?
|
| Mannans | 1 | 2007 | 5 | 0.080 |
Why?
|
| Antifungal Agents | 1 | 2008 | 117 | 0.080 |
Why?
|
| Proteins | 1 | 2013 | 777 | 0.080 |
Why?
|
| Galactose | 1 | 2007 | 32 | 0.080 |
Why?
|
| Bacteremia | 1 | 2008 | 99 | 0.080 |
Why?
|
| Genetic Testing | 1 | 2011 | 535 | 0.080 |
Why?
|
| Mice | 1 | 2021 | 11352 | 0.080 |
Why?
|
| Epigenesis, Genetic | 2 | 2022 | 479 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 2262 | 0.070 |
Why?
|
| Sinusitis | 1 | 2008 | 210 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2019 | 504 | 0.070 |
Why?
|
| Computer Simulation | 2 | 2020 | 1078 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 1313 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 1169 | 0.060 |
Why?
|
| Quality of Life | 2 | 2022 | 1585 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2008 | 746 | 0.060 |
Why?
|
| Radioisotopes | 1 | 2022 | 45 | 0.060 |
Why?
|
| Mitotic Index | 1 | 2022 | 20 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 273 | 0.050 |
Why?
|
| Monitoring, Intraoperative | 1 | 2022 | 109 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2021 | 91 | 0.050 |
Why?
|
| 5-Methylcytosine | 1 | 2022 | 112 | 0.050 |
Why?
|
| Review Literature as Topic | 1 | 2020 | 21 | 0.050 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2020 | 28 | 0.050 |
Why?
|
| Models, Economic | 1 | 2020 | 60 | 0.050 |
Why?
|
| Markov Chains | 1 | 2020 | 125 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 138 | 0.040 |
Why?
|
| North America | 1 | 2020 | 180 | 0.040 |
Why?
|
| Parenchymal Tissue | 1 | 2019 | 6 | 0.040 |
Why?
|
| Conversion to Open Surgery | 1 | 2019 | 11 | 0.040 |
Why?
|
| Unsupervised Machine Learning | 1 | 2019 | 7 | 0.040 |
Why?
|
| CpG Islands | 1 | 2019 | 151 | 0.040 |
Why?
|
| Blood Loss, Surgical | 1 | 2019 | 112 | 0.040 |
Why?
|
| Maryland | 1 | 2017 | 35 | 0.040 |
Why?
|
| Portal Pressure | 1 | 2017 | 3 | 0.040 |
Why?
|
| Liver Circulation | 1 | 2017 | 30 | 0.040 |
Why?
|
| Ligation | 1 | 2017 | 51 | 0.040 |
Why?
|
| Multiple Endocrine Neoplasia | 1 | 2017 | 7 | 0.040 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2017 | 27 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 364 | 0.040 |
Why?
|
| Random Allocation | 1 | 2017 | 332 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 410 | 0.040 |
Why?
|
| Organ Size | 1 | 2017 | 364 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2020 | 572 | 0.030 |
Why?
|
| Swine | 1 | 2017 | 555 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 702 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 303 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2015 | 290 | 0.030 |
Why?
|
| Tissue Embedding | 1 | 2014 | 6 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2014 | 70 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 235 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 357 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2018 | 426 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 751 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2014 | 782 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2012 | 73 | 0.030 |
Why?
|
| Bilirubin | 1 | 2012 | 125 | 0.030 |
Why?
|
| Cell Dedifferentiation | 1 | 2012 | 8 | 0.030 |
Why?
|
| Liver Failure | 1 | 2012 | 78 | 0.030 |
Why?
|
| PAX8 Transcription Factor | 1 | 2011 | 23 | 0.030 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2012 | 13 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2012 | 66 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2011 | 21 | 0.030 |
Why?
|
| Decision Trees | 1 | 2012 | 63 | 0.030 |
Why?
|
| Glasgow Coma Scale | 1 | 2012 | 65 | 0.030 |
Why?
|
| Italy | 1 | 2012 | 106 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 1 | 2011 | 50 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2011 | 50 | 0.030 |
Why?
|
| Genes, ras | 1 | 2011 | 96 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2705 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2012 | 111 | 0.030 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2011 | 51 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2012 | 258 | 0.020 |
Why?
|
| Angiography | 1 | 2012 | 208 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 334 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2012 | 157 | 0.020 |
Why?
|
| Thyrotropin | 1 | 2012 | 280 | 0.020 |
Why?
|
| Mastectomy, Segmental | 1 | 2011 | 93 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2012 | 349 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 689 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 752 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 1204 | 0.020 |
Why?
|
| Edetic Acid | 1 | 2008 | 43 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2012 | 373 | 0.020 |
Why?
|
| Citric Acid | 1 | 2008 | 38 | 0.020 |
Why?
|
| Bacterial Adhesion | 1 | 2008 | 84 | 0.020 |
Why?
|
| Wrist Joint | 1 | 2008 | 23 | 0.020 |
Why?
|
| Hand Strength | 1 | 2008 | 51 | 0.020 |
Why?
|
| Range of Motion, Articular | 1 | 2008 | 154 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2011 | 926 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2012 | 1578 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 2261 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 1830 | 0.010 |
Why?
|